Poland · Delayed Price · Currency is PLN Diagnostyka Earnings Call Transcripts
Fiscal Year 2025
-
Revenue grew 23.6% year-over-year, driven by strong B2B and public health program growth, with EBITDA up 15% and net profit up nearly 13%. Regulatory changes in DI and SAP implementation pose short-term challenges, but stable margins and robust cash flow support continued investment and dividends.
-
Q3 2025 saw revenue up 26% year-on-year and recurring EBITDA over PLN 150 million, driven by higher test volumes, price increases, and diagnostic imaging. Strong cash flow and robust financials support ongoing acquisitions and innovation, with stable outlook and dividend policy.
-
Test volumes and profits rose year-over-year, with revenue up 22.5% and EBITDA up 24%. Strong cash flow and disciplined capital allocation support ongoing M&A and dividend policy, while wage increases and seasonality may pressure margins in H2.
-
Q1 2025 saw strong revenue and EBITDA growth, driven by higher test volumes, price increases, and diagnostic imaging expansion. Cash flow and balance sheet remain robust, with stable margins and a positive outlook for continued growth and M&A activity.